HSF PHARMACEUTICALS has a total of 12 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2004. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are GENETHOR GMBH, BIOVEC LLC and GENEIUS BIOTECHNOLOGY INVESTMENTS LLC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Japan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Voellmy Richard | 11 |
#2 | Vilaboa Nuria | 2 |
#3 | Richard Voellmy | 1 |
#4 | Bloom David C | 1 |
Publication | Filing date | Title |
---|---|---|
EP3762024A1 | Localized activation of virus replication boosts herpesvirus-vectored vaccines | |
EP3653716A1 | Replication-competent controlled alpha-herpesvirus virus vectors and uses therefore | |
WO2018050656A2 | Inhibitors of heat shock factors and uses thereof | |
CN106794243A | Novel immune agent and its application method | |
AU2004297412A1 | Viral vectors controlled by a gene switch |